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Purpose: Matrix metalloproteinase-2 (MMP-2) and MMP-7 have been implicated in tumor growth and metastasis. This study 
aimed to investigate the expressions of MMP-2 and -7 in colorectal cancer and to evaluate their values as prognostic markers. 
Methods: Immunohistochemical staining for MMP-2 and -7 was done in 144 resected colorectal cancer specimens. Clini-
copathological data and survival results were compared with regard to the expression results. 
Results: The expression rates of MMP-2 in tumor cells in the tumor center and the tumor border were 16.7% and 38.9%, 
respectively. That of MMP-2 in stromal cells was 27.8%. MMP-7 immunoreactivities of tumor cells in the tumor center and 
the tumor border were 6.9% and 23.6%. The expressions of MMP-2 and MMP-7 were correlated. MMP-2 expression in stro-
mal cells was more increased in the distal part of the colorectum: 8.8% in right colon cancer, 29.5% in left colon cancer and 
36.4% in rectal cancer. MMP-2 expression of tumor cells in the tumor border was correlated with T-stage. MMP-7 expres-
sion of tumor cells in the tumor border was increased in case of infiltrative cancer compared with fungating tumor. The ex-
pression patterns of MMP-2 and -7 were not correlated with other clinicopathological factors, including tumor markers, 
node metastasis, distant metastasis, lymphatic invasion, tumor differentiation, and recurrence. No significant associations 
between the overall and disease-free survival rates and the MMP-2 and -7 expression patterns were noted.
Conclusion: The high expression rates of MMP-2 and -7 in tumor borders suggest that MMP-2 and -7 have some role in tu-
mor invasion, but in this study, MMP-2 and -7 did not appear to be significant predictors of prognosis in colorectal cancer.
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sion and migration, and secretion of growth factors, cytokines, 
vascular growth factors. Studies on MMP have been conducted in 
breast cancer, pancreatic cancer, lung cancer, colorectal cancer, 
ovarian cancer, prostate cancer, and brain cancer, and based on 
those studies, cancer treatment that apply MMP suppressors have 
been attempted [2].
According to the 2008 Korean survey, colorectal cancer is the 
4th leading cause of death (9.9%) among all cancers, and recently, 
it has shown an increasing trend in Korea [3]. The prognosis for 
colorectal cancer is relatively good. Nonetheless, the 5-year sur-
vival rate of TNM stage III cancer with lymph node metastasis is 
merely 25-60%. In this stage, postoperative adjuvant chemother-
apy has been reported to improve the prognoses for patients; how-
ever, many patients die due to recurrence and metastasis of the can-
cer. In stage II cancer without lymph node metastasis, the effect of 
chemotherapy is not clear yet [4]. In colorectal cancer, the most 
important prognostic factor is, of course, the stage of tumor. Nev-
ertheless, it is important to find new prognostic factors as a basis 
for determining the prognoses for patients, follow-ups, and post-
INTRODUCTION
Matrix metalloproteinases (MMPs) are enzymes that degrade ex-
tracellular matrices. These enzymes mediate not only normal phys-
iological functions, such as tissue remodeling and development of 
organs, they also play a role in pathologic condition, such as regu-
lation of inflammatory reactions, tumor growth and metastasis [1]. 
The roles of MMP in cancer growth and metastasis are related to 
their degradation of extracellular matrices, pertinent to cell adhe-
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surgical treatments. MMPs have been investigated in regard to tu-
mor growth and metastasis, and in colorectal cancer, they have 
been reported to play an important role in the development and 
growth of tumors and in the metastasis process [5]. However, the 
results of studies that examined whether MMPs were significant 
prognostic factors in colorectal cancer are contradictory in many 
cases [2]. The authors examined the expressions of MMP-2 and 
MMP-7 in colorectal cancer, and their significance as prognostic 
factors was examined by investigating the expression characteris-
tics, the association with other pathological findings, and the as-
sociation with the prognoses for patients.
METHODS
Subjects 
The study was conducted on 144 patients who were diagnosed as 
having as colorectal adenocarcinoma and who underwent a resec-
tion from January 1998 to August 2004.
Clinicopathological factors
Based on clinical records and pathology reports, the location of 
the tumor, serum CEA, T-stage, lymph node metastasis, distant 
metastasis, pathological differentiation grade, lymphatic invasion, 
macroscopic morphology of tumor, and recurrence were exam-
ined. Based on the splenic flexure, the area of the colon was classi-
fied based as the right colon or the left colon. The upper border of 
the rectum was defined as being 15 cm away from the anal verge. 
For the prognoses for patients, we analyzed the overall survival 
rate and the disease-free survival rate. Follow-up observations were 
performed until December 2009, and the average follow-up ob-
servation period was 61.8 months (range, 2 to 133 months). Sur-
vivals were assessed based on clinical records and telephone inter-
views.
Immunohistochemical staining methods
Tissue arrays were prepared by consigning them to the SuperBio-
Chips, Co. (Seoul, Korea). Tissue array blocks were sectioned with 
4-μm thicknesses, and immunohistochemical staining was per-
formed. Paraffin was removed, and to suppress endogenous per-
oxidase, the samples were treated with 0.3% hydrogen peroxide. 
The samples were reacted with primary anti-MMP-2 antibody 
(clone A-Gel VC2, 1:400 dilution; Neomarkers, Fremont, CA, USA) 
or primary anti-MMP-7 antibody (clone ID-2, 1:1,500 dilution; 
Chemicon, Temecula, CA, USA) at room temperature for 1 hour, 
washed with phosphate-buffered saline, reacted with biotynylated 
secondary antibody, and incubated with avidin-biotin streptavi-
din-peroxidase complex (Vectastatin Elite ABC kit; Vector Labo-
ratories, Burlingame, CA, USA). As dyes, 3,3´-diaminobenzidine 
tetrahydrochloride was used, and counter staining was done with 
Mayer’s hemotoxylin. The negative control group was stained by 
using the identical procedure, but omitting the first antibody. Im-
munohistochemical staining of the specimens was evaluated by 
one pathologist (a co-author). The criterion for a positive expres-
sion was more than 10% of the cytoplasm showing a distinct ex-
pression higher than moderate levels. In regard to MMP-2, the ex-
pressions in the central and the border areas of the tumors and in 
the interstitium around stumor cells were examined. In regard to 
MMP-7, only the expressions in the centers of tumor cells and in 
the border areas of the tumors were examined. MMP-2 has been 
reported to be primarily produced by interstitial tissues and MMP-7 
to be primarily produced and expressed by epithelial cells [6]. In 
the preliminary experiments of our study, no expression of MMP-7 
in the interstitium was observed; thus, the expression of MMP-7 
in the interstitium was not examined.
Statistical analysis methods
For the comparison of categorical data, the chi-square test was ap-
plied. Survival rates were obtained by using the Kaplan-Meier 
method and were compared by using the Log-Rank method. Sta-
tistical significance was associated with a P < 0.05.
RESULTS
Expressions of MMP-2 and MMP -7 and their correlation
MMP-2 was expressed in the central area of the tumor in 24 cases 
(16.7%), in the border area in 56 cases (38.9%), and in the inter-
stitium in 40 cases (27.8%). MMP-7 was expressed in the central 
area of the tumor in 10 cases (6.9%) and in the border area in 34 
cases (23.6%) (Fig. 1, Table 1). The expression of MMP-2 in the 
central area correlated significantly to the expression MMP-2 in 
the border area (P < 0.001) and to the expression of MMP-7 in the 
central area (P = 0.04). The expression of MMP-2 in the border 
area correlated significantly to the expression of MMP-2 in inter-
stitial tissues (P = 0.001), the expression of MMP-2 in interstitial 
tissues significantly correlated to the expression of MMP-7 in the 
border area (P = 0.004), and the expression of MMP-7 in the cen-
tral area correlated significantly to the expression of MMP-7 in the 
border area (P = 0.005) (Table 2).
Comparison of the expressions of MMP with 
clinicopathological factors 
When expressions of MMP were compared with clinicopatholog-
ical factors, positive expressions of MMP-2 in the border areas in 
the right colon, the left colon, and the rectum were observed in 8 
out of 34 patients (23.5%), in 18 out of 44 patients (40.9%), and in 
30 out of 66 patients (45.5%), respectively. A trend was noted in 
Table 1. Expressions of MMP-2 and -7 in tumors and stromas
  Tumor center   Tumor border  Stroma
MMP-2 expression   24/144 (16.7)   56/144 (38.9) 40/144 (27.8)
MMP-7 expression 10/144 (6.9) 34/144 (3.6) Not done
Values are presented as no./no. of total (%).
MMP, matrix metalloproteinase.Journal of The Korean Society of
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that MMP-2 was expressed more toward the distal bowel (P = 
0.098). The expression according to T stage was 11.1% in T1 (1/9), 
33.3% in T2 (5/15), 46.2% in T3 (49/106), and 7.1% in T4 (1/14) 
(P = 0.001). Concerning the expression of MMP-2 in interstitial 
tissues, the positive rate for the right colon was 8.8% (3/34), that 
for the left colon was 29.5% (13/44), and that for the rectum was 
36.4% (24/66). Expression was clearly higher toward the distal 
bowel (P = 0.014). MMP-7 was expressed in the border area of the 
tumor in 21 out of 109 fungating tumor cases (19.3%), and in in-
filtrative cases, it was expressed in 13 out of 35 cases (37.1%) (P = 
0.04). Tumor markers, lymph node metastasis, distant metastasis, 
tumor differentiation grade, lymphatic duct invasion, and recur-
rence were examined. Nevertheless, factors that correlated to the 
expression of MMP were not found (Table 3). The association of 
the expression of MMP-2 or MMP-7 in the central area of the tu-
mor with clinicopathological factors was also examined, but no 
statistically significance differences were found.
Expressions of MMP-2 and MMP-7 and the prognosis for 
the patient
Among 144 patients, in the 136 patients who underwent curative 
resection, the overall survival rate and the disease-free survival rate 
according to the expressions of MMP-2 and MMP-7 were exam-
ined. The 5-year survival rate of the patients with positive expres-
sion of MMP-2 in the border area was 75.3%, and that of patients 
with negative expression was 73.6% (P = 0.7955) (Fig. 2). The 5- 
year survival rate of patients with positive MMP-2 expression in 
interstitial tissues was 75.2%, and that of patients with negative ex-
pression was 74.0% (P = 0.7340) (Fig. 3). The 5-year survival rate 
of patients with positive MMP-7 expression in the border area was 
79.9%, and that of patients with negative expression was 72.8% (P = 
0.5175) (Fig. 4). The 5-year disease free survival rates of patients 
with positive and negative expressions of MMP-2 in the border 
area were 68.4% and 70.3% (P = 0.8290), respectively. The 5- year 
disease-free survival rates for patients with positive and negative 
expressions of MMP-2 in interstitial tissues were 65.3% and 71.1% 
(P = 0.8171), respectively. The 5-year disease-free survival rates of 
patients with positive and negative expressions of MMP-7 in the 
border area were 66.1% and 70.5%, respectively, but this difference 
was not statistically significant (P = 0.7682). The association of the 
A D C B
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Fig. 1. Immunohistochemical staining results: (A) Matrix metallo-
proteinase (MMP)-2, negative expression in tumor cells or stromal 
cell (× 100), (B) MMP-2, tumor cell (-), stromal cell (+) (× 200), (C) 
MMP-2, tumor cell (+), stromal cell (-)(× 200), (D) MMP-2, tumor 
cell (+), stromal cell (+)(× 200), (E) MMP-7, tumor center, tumor 
cell (+)(× 200), and (F) MMP-7, tumor border, tumor cell(+)(× 200).
Table 2. Relationship of MMP-2 and MMP-7 expressions in different 
areas
MMP-2  
border
MMP-2  
stroma
MMP-7  
center
MMP-7  
border
MMP-2 center
a <0.001 0.405 0.040 0.160
MMP-2 border
b 0.001 0.156 0.128
MMP-2 stroma
c 0.104 0.004
MMP-7 center
d 0.005
Values are presented as P-values. 
MMP, matrix metalloproteinase.
aTumor cell in the central tumor site. 
bTumor cell in the tumor’s border. 
cStromal 
cell adjacent to a tumor cell. 
dTumor cell in the central tumor site.Journal of The Korean Society of
Coloproctology
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expressions of MMP-2 or MMP-7 in the central area of the tumor 
with prognosis was examined, but no significant result was found.
DISCUSSION
MMPs are kinds of enzymes that degrade extracellular matrices, 
and they act under both normal physiologic and pathologic con-
ditions. Twenty-four types of MMPs, including 5 types of secreted 
MMPs and 3 types of membrane bound MT-MMPs, have been 
reported. In regard to tumors, most MMPS are produced and se-
creted by interstitial tissues in the vicinity of the tumor in response 
to the stimulation of tumor cells [7]. Until recently, MMPs have 
been reported to exert effects on the process of tumor invasion and 
metastasis. Recently, they have also been reported to play an im-
portant role in the early development of tumors [8].
In regard to the early oncogenic process of colorectal cancer, pri-
marily MMP-7 has been investigated. In a study that examined the 
expression of MMP-7 in dysplasia that developed in ulcerative coli-
tis, in low-grade dysplasia, it was shown to be expressed less, and 
in high-grade dysplasia and cancer, the expression of MMP-7 was 
clearly shown, thus establishing that MMP-7 played a role in the 
early phase of cancer development [9]. In addition, in a study con-
Table 3. Relationship between the expression of MMP and the clinicopathological factors
MMP-2 border
a P-value MMP-2 stroma
b P-value MMP-7 border
c P-value
Tumor location
   Right colon   8/34 0.098   3/34 0.014   8/34 0.546
   Left colon 18/44 13/44   8/44
   Rectum 30/66 24/66 18/66
CEA (ng/mL)
   >5  12/35 0.599 13/35 0.174   8/35 0.951
   ≤5    42/107   27/107   25/107
T stage
   T1 1/9 0.010 2/9 0.758 2/9 0.958
   T2   5/15   3/15   3/15
   T3   49/106   32/106   25/106
   T4   1/14   3/14   4/14
Node metastasis
   Present 29/73 0.344 22/73 0.522 21/73 0.140
   Absent 27/71 18/71 13/71
Distant metastasis
   Present   3/12 0.303   2/12 0.369   4/12 0.408
   Absent   53/132   38/132   30/132
Differentiation
   Well to moderately   47/125 0.416   35/125 0.879   27/125 0.145
   Poorly   9/19   5/19   7/19
Lymphatic invasion
   Positive   49/125 0.844   35/125 0.879   32/125 0.149
   Negative   7/19   5/19   2/19
Gross findings of the tumor
   Fungating   41/109 0.580   31/109 0.754   21/109 0.040
   Infiltrating 15/35   9/35 13/35
Recurrences
   Present 18/42 0.546 13/42 0.407 12/42 0.329
   Absent 34/91 22/91 19/91
MMP, matrix metalloproteinase; CEA, carcinoembryonic antigen.
aPositive expression of MMP-2 in the tumor’s border area. 
bPositive expression of MMP-2 in stromal tissue. 
cPositive expression of MMP-7 in the tumor’s border area.Journal of The Korean Society of
Coloproctology
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In our study, the expression of MMP-2 in tumor tissues and in-
terstitial tissues, as well as the expression of MMP-7 in tumor tis-
sues, were examined by immunohistochemical staining. Others 
have reported that MMP-7 is produced by epithelial cells and that 
it is not expressed in the interstitium [6, 13]. In our preliminary 
experiments, MMP-7 was not expressed in the interstitium. MMP-2 
was expressed in the central areas of the tumors in 16.7% of the 
cases, and in the border areas in 38.8% of the cases. MMP-7 was 
expressed in the central areas of tumors in 6.9% of the cases, and 
in the border areas in 23.6% of the cases. This is in agreement with 
the results of most studies that examined the expressions of MMP-2 
and MMP-7 by immunohistochemical staining; i.e., MMP was 
strongly expressed in the borders of the tumors, in other ward, in 
cancer cells in the front lines of cancers that invade normal tissues 
[10, 13-16].
Previous studies have reported that MMP-2 is produced primarily 
by fibroblasts in interstitial tissues and is activated in tumor cells [17] 
and that during the process, the mutual action of tumor cells and 
interstitial cells is important [18]; this can be explained by MMP-2 
being expressed strongly in the border areas of tumors where tu-
mor and interstitial tissues are abundant. MMP-7 was also observed 
to be expressed strongly in the border areas of tumors, and similar 
to MMP-2, this was explained by some investigators as being due 
to the mutual interaction of tumors and host cells [16]. Such strong 
expression of MMP in the border area is thought to accelerate the 
degradation of the tumor matrix and to activate tumor invasion 
and metastasis.
No studies have reported expressions in the central area and the 
border area separately as our study has done. Most studies exam-
ined and reported the expression of MMP in the border area, and 
MMP-2 was expressed in 35-87% of the cases [13-15], and MMP-7 
was expressed in 54-84% of the cases [13, 14, 19]. In our study, the 
expression rate was low, but the standards for evaluation were dif-
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Fig. 2. Survival curve according to matrix metalloproteinase (MMP)-2 
expression on the tumor’s border: solid line (negative expression of 
MMP-2) and broken line (positive expression of MMP-2).
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Fig. 4. Survival curve according to matrix metalloproteinase (MMP)-7 
expression on the tumor’s border: solid line (negative expression of 
MMP-7) and broken line (positive expression of MMP-7).
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Fig. 3. Survival curve according to matrix metalloproteinase (MMP)-2 
expression on a stromal cell: solid line (negative expression of MMP-
2) and broken line (positive expression of MMP-2).
ducted on liver metastasis of colorectal cancer, Zeng et al. [10] ex-
amined the expression of MMP-7 and observed that MMP-7 mRNA 
and enzyme activity were over-expressed in metastatic cancer tis-
sues in comparison with normal liver tissues, and in immunohis-
tochemical staining, the border area of the cancer showed strong 
expression of MMP-7; thus, MMP-7 played an important role in 
liver metastasis of colorectal cancer.
Some investigations of the association of MMP-2 expression with 
distant metastasis of colorectal cancer have been performed. Brand 
et al. [11] reported a significant reduction of liver metastasis in an-
imal experiments using the gene of the MMP-2 suppressor, the tis-
sue inhibitor of MMP-2 (TIMP-2). In patients with the elevated 
levels of plasma MMP-2, lymph node metastasis has been reported 
to occur more frequently [12].Journal of The Korean Society of
Coloproctology
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ferent; thus, objective comparisons are difficult. In our study, the 
expression of MMP-2 in the border areas of tumors and in the in-
terstitium were 38.9% and 27.8% (P = 0.001). This may be ex-
plained sufficiently by the mutual relation of tumor cells and in-
terstitial tissues that was described above. In regard to the site of 
the expression of MMP-2, Schwandner et al. [13] reported that it 
was expressed in tumor cells in 35% of the cases and in the inter-
stitium in 77% of the cases. Hilska et al. [14] reported that MMP-2 
expressions in tumor cells and in the interstitium were compara-
ble in 87% of the cases. Papadopoulou et al. [20] reported that 
MMP-2 was expressed in tumor cells in 44% of the cases and in 
the interstitium in approximately 50% of the cases. Nonetheless, 
the staining intensity of the interstitium was weaker than that of 
tumor cells. Such differences appear to be due to differences in re-
search and assessment methods.
In our study, in the central areas of tumors, the expressions of 
MMP-2 and MMP-7 correlated (P = 0.04), and in the interstitium, 
the expression of MMP-2 was associated with the expression of 
MMP-7 in tumors in the vicinity (P = 0.004). This is a result that 
is in agreement with research reports showing that MMP-7 con-
tributes to the activation of pro–MMP-2 [21].
When the expression of MMP is compared with clinicopatholog-
ical factors, MMP-7 was expressed in the border areas of macro-
scopic elevated type tumors in 19.3% of the cases, in invasive type 
tumors with unclear borders, it was expressed in 37.1% of the cases 
(P = 0.03), and in areas where tumor invasion was active, it was 
found to be expressed well. However, it was not associated with dis-
ease stage, tumor differentiation grade, tumor markers, lymphatic 
duct invasion, distant metastasis, and recurrence. In regard to the 
expression of MMP-2 in the interstitium, it was expressed in the 
right colon in 8.8% of the cases, in the left colon in 29.5% of the 
cases, in the rectum in 36.4% of the cases; toward the distal bowel, 
it was expressed more (P = 0.014). In the colon, the expression of 
MMP-2 in interstitial tissues was 20.5%, and in the rectum, it was 
36.4%, and that difference was significant (P = 0.034). This is dif-
ferent from the results of other studies in which the expressions of 
MMP-2 in the colon and the rectum were not different [22, 23]. 
Nevertheless, because of the different study methods, the results 
are difficult to compare. However, MMP-2 is produced mainly in 
the interstitium [24]; thus more significant results may be obtained 
by assessing the expression in the interstitium. The expression of 
MMP-2 did not correlate to the prognostic factors of colorectal can-
cer patients, such as tumor stage, tumor cell differentiation grade, 
tumor markers, lymphatic duct invasion, distant metastasis, and 
recurrence.
In our study, the prognoses of patients based on the expressions 
of MMP-2 and MMP-7 were not different. Concerning this point, 
many studies have reported contradictory results. Cho et al. [25] 
reported that MMP-2 was not associated with several clinicopath-
ological factors that show tumor invasiveness. Schwandner et al. 
[13] also reported that in rectal cancer, MMP-2 and MMP-7 ex-
pressions were not associated with prognosis. On the other hand, 
Hilska et al. [14] reported that the prognosis of colon cancer pa-
tients with the expression of MMP-2 was poor. Sundov et al. [15] 
reported that in disease stage Duke’s B colon cancer patients, the 
expression of MMP-2 was a poor prognostic factor. Adachi et al. 
[16] reported that the expression of MMP-7 was an independent 
prognostic factor in patients with colorectal cancer. By measuring 
the serum MMP-7 of patients, Maurel et al. [26] observed that it 
was elevated in cases of advanced colorectal cancer, and that it was 
an independent prognostic factor. Because of such varying reports, 
it appears to be difficult to answer definitely the question of whether 
a specific MMP is a significant prognostic factor. As neovascular-
ization of a tumor is achieved by the coordination of its stimulat-
ing factors and antagonistic factors, the action of MMP, which is 
associated with tumor invasion and metastasis, must be understood 
within its relationship with the inhibitory factors that areTIMP [27].
In colorectal cancer, MMP-2 and MMP-7 were expressed more 
strongly in the border areas of tumors than in the central areas. In 
our study, the expressions of MMP-2 or MMP-7 did not signifi-
cantly correlate to an advanced level of cancer; similarly, it had no 
correlation with the prognoses for patients.
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